The purpose of the study is to compare the effect in blood sugar control between Lantus and
twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a
multiple daily injection setting with fast acting insulin (Lispro)
- Type 1 diabetes treated with insulin only for at least 1 year,
- with a Tanner stage of ≥ 2,
- had evidence of decreased insulin secretory capacity (fasting C-peptide concentration
≤0.5 mmol/L) and 7.0%≤A1c≤9.5% at screening.
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.